BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Response to oxidative stress
,
Influenza
,
Heart
,
Autoimmunity
,
Rosiglitazone
,
GATA1
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Tyr3
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
No tissues found
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
No diseases found
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
No compounds found
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
No perturbed genes found
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
No studies found
Explore Curated Studies Results
Literature
Most Relevant Literature
Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Ty…
Extraventricular neurocytoma treated with 177Lu DOTATATE PRRT induction and maintenance therapies.
Accuracy of DOTATATE PET imaging in the preoperative planning of small bowel neuroendocrine tumor re…
68Ga-DOTATATE PET/CT versus 111In-octreotide scintigraphy in patients with neuroendocrine tumors: a …
Dynamic 68Ga-DOTA0-Tyr3-octreotate positron emission tomography-computed tomography for the evaluati…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inop…
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ